KR20180118667A - 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 - Google Patents

만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 Download PDF

Info

Publication number
KR20180118667A
KR20180118667A KR1020187026084A KR20187026084A KR20180118667A KR 20180118667 A KR20180118667 A KR 20180118667A KR 1020187026084 A KR1020187026084 A KR 1020187026084A KR 20187026084 A KR20187026084 A KR 20187026084A KR 20180118667 A KR20180118667 A KR 20180118667A
Authority
KR
South Korea
Prior art keywords
dose
cyanobenzoyl
amino
pyrazol
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187026084A
Other languages
English (en)
Korean (ko)
Inventor
콜린 오포드
시릴 클라크
콜름 패럴
재클린 파킨
스테판 드 벅
Original Assignee
메레오 바이오파마 1 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메레오 바이오파마 1 리미티드 filed Critical 메레오 바이오파마 1 리미티드
Priority to KR1020247020223A priority Critical patent/KR102762199B1/ko
Publication of KR20180118667A publication Critical patent/KR20180118667A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187026084A 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 Ceased KR20180118667A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247020223A KR102762199B1 (ko) 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2016/050636 WO2017153702A1 (en) 2016-03-08 2016-03-08 Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247020223A Division KR102762199B1 (ko) 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법

Publications (1)

Publication Number Publication Date
KR20180118667A true KR20180118667A (ko) 2018-10-31

Family

ID=55586330

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187026084A Ceased KR20180118667A (ko) 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법
KR1020247020223A Active KR102762199B1 (ko) 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247020223A Active KR102762199B1 (ko) 2016-03-08 2016-03-08 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법

Country Status (9)

Country Link
US (2) US10603306B2 (enExample)
JP (1) JP6741774B2 (enExample)
KR (2) KR20180118667A (enExample)
AU (1) AU2016397047B2 (enExample)
BR (1) BR112018067454A2 (enExample)
CA (1) CA3016488C (enExample)
MX (1) MX385717B (enExample)
RU (1) RU2713203C1 (enExample)
WO (1) WO2017153702A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200097310A (ko) * 2017-12-11 2020-08-18 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 예방 또는 감소에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385717B (es) * 2016-03-08 2025-03-18 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
GB201612238D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
JP7280627B2 (ja) * 2017-12-11 2023-05-24 メレオ バイオファーマ １ リミテッド 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
CN1832928B (zh) 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US20050277602A1 (en) 2004-05-21 2005-12-15 Grunstein Michael M Methods employing agonists of P38 map kinase for the treatment of asthma
US20090270350A1 (en) 2006-02-10 2009-10-29 Pfizer Inc. Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
LT2827860T (lt) * 2012-03-20 2016-12-12 Mereo Biopharma 1 Limited Pirazolo darinio panaudojimas stiprių lėtinės obstrukcinės plaučių ligos paūmėjimų gydymui
MX385717B (es) * 2016-03-08 2025-03-18 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
KR20180119597A (ko) * 2016-03-08 2018-11-02 메레오 바이오파마 1 리미티드 염증 상태의 급성 악화의 치료를 위한 투약법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200097310A (ko) * 2017-12-11 2020-08-18 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 예방 또는 감소에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도

Also Published As

Publication number Publication date
BR112018067454A2 (pt) 2019-01-15
US20190060279A1 (en) 2019-02-28
CA3016488C (en) 2023-04-11
JP2019507786A (ja) 2019-03-22
US20200281896A1 (en) 2020-09-10
WO2017153702A1 (en) 2017-09-14
KR20240101698A (ko) 2024-07-02
MX2018010782A (es) 2019-01-10
US11129810B2 (en) 2021-09-28
AU2016397047A1 (en) 2018-09-06
CA3016488A1 (en) 2017-09-14
AU2016397047B2 (en) 2022-04-07
US10603306B2 (en) 2020-03-31
MX385717B (es) 2025-03-18
KR102762199B1 (ko) 2025-02-07
JP6741774B2 (ja) 2020-08-19
RU2713203C1 (ru) 2020-02-04

Similar Documents

Publication Publication Date Title
US11129810B2 (en) Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
RU2709509C1 (ru) Режим дозирования для лечения острых обострений воспалительных состояний
ES2882978T3 (es) Uso de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciclopropil-4-metilbenzamida en la prevención de exacerbaciones agudas de la enfermedad de obstrucción pulmonar crónica
AU2018382895B2 (en) Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
KR102899004B1 (ko) 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
HK40020426A (en) Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
HK40020426B (en) Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104